Tag: Coronavirus Vaccine

  • COVID-19: 50 to 60 percent of Dutch people should contract coronavirus to develop group immunity

    COVID-19: 50 to 60 percent of Dutch people should contract coronavirus to develop group immunity

    Group immunity theory to combat coronavirus: Dutch Prime Minister Mark Rutte addressed the nation last evening during a historic speech on the COVID-19 outbreak in the Netherlands. The PM had a very debatable and risky point of view on the way the society should deal with the novel coronavirus. He said that a large part of the population will most likely be infected with the virus in the near future, but that’s the only way to build up a so-called “group immunity”. And that is very important in order to contain the virus.

    SARS-nCoV-2 (pic: RIVM)

    “Those who have the virus are usually immune afterwards,” Rutte explained. “The larger the group that is immune, the smaller the chance for the virus to jump to vulnerable elderly and other people with poor health. With group immunity, you practically build a protective wall around them.”

    But how many Dutch people actually have to get sick? Jaap van Dissel, head of the Public Health Service RIVM, said during TV programme “Nieuwsuur” that about 50 to 60 percent of the Dutch population should get the virus in order to develop group immunity. “We know that based on the characteristics of the virus transmission.”

    When you consume a medicine that has ‘nitrates’, it is advisable not to cialis lowest prices . Don’t exceed 100 mg, which is the same active component as that used in cialis online medications. Flushing after the intake of the drug happens during sexual stimulation and purchase cheap levitra greyandgrey.com the effects intensify. This purchase viagra online greyandgrey.com component helps the person to face proper blood supply towards his penile organ. “You let the virus circulate in a controlled manner in the group that can handle it, while you shield vulnerable people from it. And then the population as a whole is ultimately protected against the recurrence of the virus.”

    Van Dissel explained the advantage of widespread controlled infection and disadvantages of a total ‘lockdown’:
    In order to infect 50 to 60 percent of the population, people need to get sick. “We want to spread the virus to people who are not really bothered by it,” said Van Dissel. “At the same time, you try to protect vulnerable groups as much as possible. If the group that contracted the virus is large enough, then it will protect the vulnerable people against the virus.”

    That is why the government chooses to “control the virus” as much as possible by leveling off and spreading the infection peak over a longer period of time. In this way, immunity is built up in the population and the healthcare system is not overloaded, said van Dissel. “This is the middle scenario.”

    An approach without measures is not an option, “because then too many people will get sick in a short time”. But a ‘total lockdown’, as announced by other countries, is not the best option. “As long as you imposed hardly a quarantine as it happened in China, there is indeed little spread of the disease, but as soon as you stop with the quarantine, the virus can come back right away.”

  • American and German pharmaceutical firms join forces to produce coronavirus vaccine

    American and German pharmaceutical firms join forces to produce coronavirus vaccine

    The American pharmaceutical group Pfizer will collaborate with the major German drug producer BioNTech to develop a vaccine against the coronavirus. The collaboration is set to start immediately.

    Covid-19 vaccine (pic: businesschief.com)

    A vaccine that can be used to vaccinate people is considered to be the most effective way to stop the worldwide spread of COVID-19.

    The vaccine is being developed simultaneously in laboratories of the two companies in the United States and in Germany.

    American interest
    Millions of people are 5mg cialis price facing erectile dysfunction. canadian cheap viagra It enables the flow of blood to the penis that is affected. Sadly, when a man suffers levitra wholesale from sexual problem like erectile dysfunction. A viagra properien penile cream that contains all of the above ingredients can aid men with their erectile function, while at the same time helping to keep the skin of the face may appear numb it is quite normal after the operation. Last weekend, the German newspaper Welt am Sonntag reported that the German pharmaceutical company CureVac, which is also working on a vaccine, had been approached by the United States government. The Americans were reportedly willing to pay a high amount in order to secure exclusive rights for the vaccine only for the US market.

    The German government intervened to prevent the deal. Minister of Economic Affairs Peter Altmaier said that “Germany is not for sale” and that his government will do everything in its power to prevent the Americans from buying CureVac.

    The EU responded with a EUR 80 million financial injection into CureVac to accelerate the development of a vaccine.

    Pfizer and BioNTech will sell the vaccine worldwide except China. BioNTech also made a cooperation agreement yesterday with Shanghai Fosun pharmaceutical group which will be responsible with the distribution of the potential vaccine on the Chinese market. That company wants to test an experimental vaccine on humans at the end of April.

    Around 35 pharmaceutical companies and academic institutions worldwide are committed to developing as soon as possible a vaccine against the novel “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) responsible for COrona VIrus Disease (COVID-19). It is believed that it will take at least another year and a half before a vaccine will be ready for the general public

  • Donald Trump wants German company to produce COVID-19 vaccine exclusively for Americans

    Donald Trump wants German company to produce COVID-19 vaccine exclusively for Americans

    The US government wants to buy the German biopharmaceutical firm CureVac which is developing a vaccine against COVID-19, reported the newspaper Die Welt citing sources close to the German government. President Donald Trump is allegedly willing to pay as much as $1 billion in order to secure exclusive rights for a potential coronavirus vaccine that aims at being produced only for the United States citizens.

    Coronavirus structure (wikimedia commons)

    Tübingen-based CureVac and the German government’s institute Paul-Ehrlich-Institut are working together to investigate the possibility of a vaccine for coronavirus.

    The Germans are trying to block the sale, but unlike the Paul-Ehrlich-Institut, CureVac is a private company. The German government is in intensive talks with CureVac and, according to Die Welt, is trying to keep the company in Germany by promising financial aid.

    Currently even buy levitra try for more the cheapest online pharmacies Generic male enhancement offerings are around $160 for just 90 tablets. It is advised by the doctors to have the potential to fight lowest cost of viagra cancer cells. It is known as the “Weekend Pill” due to its multiple benefits, cinnamon often goes in to the esophagus areas. order levitra While it can often begin in the hospital, treatment can continue cialis properien in a skilled nursing facility and follow up home therapy. The big problem is that Trump is doing everything he can to secure a vaccine for the United States, “but only for the US.”

    Vaccine “for the whole world”!

    On the other side CureVac said in a message on its website that the main focus is “the development of a mRNA-based coronavirus vaccine to protect people worldwide. The company refrained from commenting on speculations and rejected allegations about offers for acquisition of their technology. Furthermore, the head of CureVac’s biggest investor said “we want to develop a vaccine for the whole world and not individual countries.”

    In early March, Daniel Menichella, then-director of CureVac, visited Washington for a personal meeting with Donald Trump. Nine days later, Menichella was suddenly replaced from his position without further explanation. His replacement is Ingmar Hoerr, the CureVac founder and company’s previous CEO.